AXS Investments LLC Increases Holdings in Johnson & Johnson (NYSE:JNJ)

AXS Investments LLC grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 129.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,205 shares of the company’s stock after acquiring an additional 4,622 shares during the period. AXS Investments LLC’s holdings in Johnson & Johnson were worth $1,456,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock valued at $42,205,749,000 after acquiring an additional 3,358,478 shares in the last quarter. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 0.4% in the first quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock valued at $35,587,638,000 after acquiring an additional 777,837 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 0.8% in the first quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock valued at $5,808,286,000 after acquiring an additional 265,330 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Johnson & Johnson by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock valued at $5,683,837,000 after acquiring an additional 509,818 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after buying an additional 328,297 shares in the last quarter. 68.59% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.1 %

JNJ opened at $177.01 on Thursday. The stock has a market cap of $462.79 billion, a price-to-earnings ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57. The stock’s 50 day moving average price is $168.35 and its 200-day moving average price is $171.28. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.60 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be paid a dividend of $1.13 per share. The ex-dividend date is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. Johnson & Johnson’s dividend payout ratio is 62.95%.

Johnson & Johnson announced that its board has authorized a share repurchase program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JNJ shares. Atlantic Securities decreased their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Citigroup decreased their target price on Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Bank of America decreased their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Raymond James decreased their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Finally, StockNews.com assumed coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, VP Peter Fasolo sold 22,864 shares of the stock in a transaction that occurred on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at $18,864,202. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The disclosure for this sale can be found here. Insiders have sold a total of 212,646 shares of company stock valued at $36,791,022 over the last quarter. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.